2-(1-piperazinyl)-4-amino-6,7-dimethoxyquinazoline, also known as **GW5074**, is a chemical compound that belongs to a class of drugs called **quinazoline derivatives**.
Here's why it's important for research:
* **Potential for Anti-Cancer Activity:** GW5074 is a potent inhibitor of **cyclin-dependent kinases (CDKs)**, which are enzymes involved in cell cycle regulation. CDKs are crucial for cell division, and their uncontrolled activity is a hallmark of many cancers. By inhibiting CDKs, GW5074 can potentially prevent cancer cells from proliferating.
* **Target for Drug Development:** Due to its CDK-inhibitory properties, GW5074 has been investigated as a potential therapeutic agent for various cancers, including leukemia, lymphoma, and solid tumors. Research is ongoing to explore its efficacy and safety in preclinical and clinical studies.
* **Understanding Cell Cycle Regulation:** GW5074 serves as a valuable tool for researchers studying cell cycle regulation and cancer biology. Its ability to inhibit CDKs allows for the investigation of the specific roles of these enzymes in different cellular processes and their potential as therapeutic targets.
* **Investigational Drug:** While not currently approved for any medical use, GW5074 remains an active area of research, with ongoing efforts to develop it into a clinically viable anti-cancer drug.
**It's important to note:** GW5074 is currently only an investigational compound. Its potential benefits and risks are still being studied, and it is not available for general use.
2-(1-piperazinyl)-4-amino-6,7-dimethoxyquinazoline: prazosin metabolite; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 616267 |
| CHEMBL ID | 1226 |
| SCHEMBL ID | 608966 |
| MeSH ID | M0145301 |
| Synonym |
|---|
| EU-0016066 |
| 60547-97-9 |
| AC-17537 |
| bdbm50073568 |
| cid_616267 |
| 6,7-dimethoxy-2-piperazin-1-yl-quinazolin-4-ylamine |
| SDCCGMLS-0023979.P002 |
| 6,7-dimethoxy-2-piperazino-4-aminoquinazoline |
| CBDIVE_007723 |
| MLS000060939 , |
| smr000069167 |
| 6,7-dimethoxy-2-(1-piperazinyl)-4-quinazolinamine |
| OPREA1_697372 |
| CHEMBL1226 , |
| aminodimethoxyquinazolinylpiperazine (piperazine derivative of terazosin) |
| 6,7-dimethoxy-2-(piperazin-1-yl)quinazolin-4-amine |
| STL084882 |
| 6,7-dimethoxy-2-piperazin-1-ylquinazolin-4-amine |
| 2-piperazine-4-amino-6,7-dimethoxyquinazoline |
| 1x8ji3451k , |
| 2-(1-piperazinyl)-4-amino-6,7-dimethoxyquinazoline |
| unii-1x8ji3451k |
| 2-padqz |
| VU0000318-6 |
| AKOS005713694 |
| 0ec , |
| HMS2421B15 |
| FT-0640697 |
| 4-quinazolinamine, 6,7-dimethoxy-2-(1-piperazinyl)- |
| prazosin hydrochloride impurity c [ep impurity] |
| 4-amino-2-(1-piperazinyl)-6,7-dimethoxyquinazoline |
| n-desfuranoyl prazosin |
| prazosin metabolite m1 |
| 4-amino-6,7-dimethoxy-2-(1-piperazinyl)quinazoline |
| 2-piperazino-6,7-dimethoxy-4-quinazolinamine |
| 2-(4-piperazinyl)-4-amino-6,7-dimethoxyquinazoline |
| terazosin hydrochloride dihydrate impurity c [ep impurity] |
| 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)piperazine |
| doxazosin mesilate impurity g [ep impurity] |
| doxazosin impurity g |
| SCHEMBL608966 |
| 6,7-dimethoxy-2-piperazino-4-quinazolinylamine |
| KS-1023 |
| 2-piperazinyl-4-amino-6,7-dimethoxy quinazoline |
| 4-amino-6,7-dimethoxy-2-(1-piperazinyl)-quinazoline |
| 2-(1-piperazinyl)-4-amino-6,7-dimethoxy-quinazoline |
| 2-piperazino-4-amino-6,7-dimethoxyquinazoline |
| 4-amino-6,7-dimethoxy-2-(1-piperzinyl)quinazoline |
| 4-amino-6,7-dimethoxy-2-piperazinoquinazoline |
| 4-amino-2-piperazin-1-yl-6,7-dimethoxy-quinazoline |
| 4-amino-6,7-dimethoxy-2-piperazino-quinazoline |
| 4-amino-6,7-dimethyoxy-2-(1-piperazinyl)quinazoline |
| 4-amino-6,7-dimethoxy-2-(1-piperazinyl) quinazoline |
| 4-amino-6,7dimethoxy-2-(1-piperazinyl)quinazoline |
| 4-amino-6,7-dimethyoxy-2-(1-piperazinyl)-quinazoline |
| REGID_FOR_CID_616267 |
| mfcd00563872 |
| 4-amino-6,7-dimethoxy-2-piperazin-1-ylquinazoline |
| 4-quinazolinamine, 6,7-dimethoxy-2-(1-piperazinyl) |
| 4-amino-6,7-dimethoxy-2-(1-piperazinyl)quinqzoline |
| 6,7-dimethoxy-2-(1-piperazinyl)-4-quinazolinamine # |
| DTXSID00209293 |
| 2-piperazinyl-4-amino-6,7-dimethoxyquinazoline |
| prazosin ep impurity c |
| prazosin bp impurity c; terazosin ep impurity c; 4-amino-6,7-dimethoxy-2-(1-piperazinyl)quinazoline; 2-piperazinyl-4-amino-6,7-dimethoxyquinazoline; 6,7-dimethoxy-2-(1-piperazinyl)-4-quinazolinamine; 4-amino-2-(1-piperazinyl)-6,7-dimethoxyquinazoline |
| Q27253028 |
| 2-[(2,6-dimethylphenyl)amino]-n,n,n-trimethyl-2-oxoethanaminiumcl |
| EN300-7353400 |
| aminodimethoxyquinazolinylpiperazine |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 0.0045 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 25.1189 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 4.4668 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 31.6228 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 67.8335 | 0.1000 | 20.8793 | 79.4328 | AID588453; AID588456 |
| WRN | Homo sapiens (human) | Potency | 56.2341 | 0.1683 | 31.2583 | 100.0000 | AID651768 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 23.1093 | 0.0041 | 10.8903 | 31.5287 | AID504466 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 0.1995 | 0.1800 | 13.5574 | 39.8107 | AID1468 |
| Smad3 | Homo sapiens (human) | Potency | 35.4813 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 25.1189 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 31.6228 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 5.6234 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 31.6228 | 0.0018 | 15.6638 | 39.8107 | AID894 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 56.2341 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| DNA polymerase beta | Homo sapiens (human) | Potency | 79.4328 | 0.0224 | 21.0102 | 89.1251 | AID485314 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 56.2341 | 0.1337 | 25.4129 | 89.1251 | AID588795 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 84.9214 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 56.2341 | 0.1000 | 28.9256 | 213.3130 | AID588591 |
| geminin | Homo sapiens (human) | Potency | 12.9953 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 79.4328 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
| Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 79.4328 | 6.3096 | 60.2008 | 112.2020 | AID720709 |
| Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 10.0000 | 4.4668 | 8.3448 | 10.0000 | AID624291 |
| Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 31.6228 | 3.9811 | 46.7448 | 112.2020 | AID720708 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Apoptotic peptidase activating factor 1 | Homo sapiens (human) | IC50 (µMol) | 65.7500 | 0.0375 | 18.6232 | 53.2000 | AID588524; AID588538 |
| caspase-9 isoform alpha precursor | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0256 | 16.5070 | 52.8000 | AID588574 |
| ubiquitin-conjugating enzyme E2 N | Homo sapiens (human) | IC50 (µMol) | 1.1845 | 0.8730 | 10.7219 | 78.4000 | AID493155; AID493182 |
| caspase-3 isoform a preproprotein | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0256 | 20.3235 | 74.3000 | AID588574 |
| bcl-2-related protein A1 | Mus musculus (house mouse) | IC50 (µMol) | 11.1000 | 0.4190 | 7.7563 | 35.1000 | AID504689 |
| rac GTPase-activating protein 1 isoform a | Homo sapiens (human) | IC50 (µMol) | 63.1400 | 7.3900 | 57.8904 | 301.2400 | AID624330 |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | IC50 (µMol) | 1.0000 | 0.0004 | 0.9086 | 10.0000 | AID5488 |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 (µMol) | 0.3400 | 0.0002 | 1.8742 | 10.0000 | AID36729 |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | IC50 (µMol) | 1.0000 | 0.0003 | 1.3833 | 8.4000 | AID3765 |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 (µMol) | 1.0000 | 0.0003 | 1.0914 | 7.7625 | AID36921 |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 (µMol) | 1.0000 | 0.0003 | 1.0914 | 7.7625 | AID36921 |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 (µMol) | 1.0000 | 0.0003 | 1.0691 | 7.7625 | AID36921 |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 (µMol) | 0.3400 | 0.0002 | 1.2704 | 10.0000 | AID36729 |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 (µMol) | 0.3400 | 0.0000 | 1.8194 | 10.0000 | AID36729 |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 (µMol) | 1.0000 | 0.0001 | 0.5494 | 8.4000 | AID64437 |
| Cysteinyl leukotriene receptor 1 | Cavia porcellus (domestic guinea pig) | IC50 (µMol) | 1.0000 | 0.0009 | 0.0880 | 0.5000 | AID5488 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| beta-2 adrenergic receptor | Homo sapiens (human) | EC50 (µMol) | 8.6100 | 0.0016 | 1.8759 | 8.4400 | AID588763 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| DNA repair and recombination protein RAD54-like isoform 1 | Homo sapiens (human) | AC50 | 1.4900 | 0.8140 | 19.3119 | 78.9500 | AID651657 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID36921 | Inhibitory concentration against Alpha-2 adrenergic receptor | 1999 | Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3 | Synthesis, pharmacological evaluation, and structure-activity relationship and quantitative structure-activity relationship studies on novel derivatives of 2,4-diamino-6,7-dimethoxyquinazoline alpha1-adrenoceptor antagonists. |
| AID248936 | Antiproliferative activity was determined by colorimetric MTS assay in LNCaP cells after 72 hr of incubation with compounds (1-100 uM); Not active at 100 uM | 2005 | Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1 | Design, synthesis, and biological evaluation of prazosin-related derivatives as multipotent compounds. |
| AID36729 | Inhibition of Alpha-1 adrenergic receptor in rat cortex membrane | 1999 | Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3 | Synthesis, pharmacological evaluation, and structure-activity relationship and quantitative structure-activity relationship studies on novel derivatives of 2,4-diamino-6,7-dimethoxyquinazoline alpha1-adrenoceptor antagonists. |
| AID1557364 | Binding affinity to HCV promoter RNA by NMR-based fragment screening assay | 2019 | MedChemComm, Aug-01, Volume: 10, Issue:8 | Synthetic small-molecule RNA ligands: future prospects as therapeutic agents. |
| AID5488 | Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration) | 1999 | Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3 | Synthesis, pharmacological evaluation, and structure-activity relationship and quantitative structure-activity relationship studies on novel derivatives of 2,4-diamino-6,7-dimethoxyquinazoline alpha1-adrenoceptor antagonists. |
| AID64437 | Inhibitory concentration against Dopamine receptor D2 (Inactive at >1000 nM concentration) | 1999 | Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3 | Synthesis, pharmacological evaluation, and structure-activity relationship and quantitative structure-activity relationship studies on novel derivatives of 2,4-diamino-6,7-dimethoxyquinazoline alpha1-adrenoceptor antagonists. |
| AID1557365 | Antiviral activity against HCV infected in MDCK cells assessed as reduction in viral replication | 2019 | MedChemComm, Aug-01, Volume: 10, Issue:8 | Synthetic small-molecule RNA ligands: future prospects as therapeutic agents. |
| AID3765 | Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration) | 1999 | Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3 | Synthesis, pharmacological evaluation, and structure-activity relationship and quantitative structure-activity relationship studies on novel derivatives of 2,4-diamino-6,7-dimethoxyquinazoline alpha1-adrenoceptor antagonists. |
| AID248964 | Antioxidant activity against formation of ROS was determined in t-BuOOH treated LNCaP cells after 24 hr of incubation with compounds (1-100 uM); Not active at 100 uM | 2005 | Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1 | Design, synthesis, and biological evaluation of prazosin-related derivatives as multipotent compounds. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.51) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (9.09%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (90.91%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||